MX2020001428A - Composiciones de grapiprant y metodos para usar las mismas. - Google Patents

Composiciones de grapiprant y metodos para usar las mismas.

Info

Publication number
MX2020001428A
MX2020001428A MX2020001428A MX2020001428A MX2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A
Authority
MX
Mexico
Prior art keywords
grapiprant
human animal
compositions
methods
same
Prior art date
Application number
MX2020001428A
Other languages
English (en)
Inventor
Devaraj Gopinath
RAUSCH-DERRA Lesley
NEWBOLD Tamara
Shiraishi Akemi
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001428(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2020001428A publication Critical patent/MX2020001428A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente descripción proporciona un método para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. El método comprende la administración a un animal no humano de una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de grapiprant. También se proporcionan en la presente composiciones farmacéuticas para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. Las composiciones farmacéuticas comprenden una cantidad terapéuticamente eficaz de grapiprant y un excipiente, incluyendo saborizantes.
MX2020001428A 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas. MX2020001428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948957P 2014-03-06 2014-03-06
US201462089713P 2014-12-09 2014-12-09

Publications (1)

Publication Number Publication Date
MX2020001428A true MX2020001428A (es) 2020-03-20

Family

ID=54016294

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011025A MX2016011025A (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016011025A MX2016011025A (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Country Status (15)

Country Link
US (2) US11369621B2 (es)
EP (1) EP3113774B1 (es)
JP (1) JP6419857B2 (es)
KR (1) KR102270323B1 (es)
CN (2) CN105939713A (es)
AU (1) AU2015227059B2 (es)
CA (1) CA2941008C (es)
DK (1) DK3113774T3 (es)
ES (1) ES2907285T3 (es)
MX (3) MX2016011025A (es)
PL (1) PL3113774T3 (es)
PT (1) PT3113774T (es)
RU (1) RU2679631C2 (es)
TW (2) TWI664969B (es)
WO (1) WO2015134792A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220096501A1 (en) * 2014-12-09 2022-03-31 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
US20210353648A1 (en) * 2018-09-27 2021-11-18 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
DE60012751T2 (de) * 1999-08-10 2005-01-20 Glaxo Group Ltd., Greenford Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
IL164263A0 (en) 2002-04-12 2005-12-18 Pfizer Use of ep4 receptor ligands on the treatment of il-6 involved diseases
WO2005102389A2 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
PL1861400T3 (pl) * 2005-03-11 2010-09-30 Askat Inc Postacie krystaliczne pochodnych imidazolu
EP2013169B1 (en) * 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
US20080242713A1 (en) * 2007-03-28 2008-10-02 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
KR101780666B1 (ko) 2010-02-22 2017-09-21 에스크엣 인크. Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도
US20130225609A1 (en) * 2010-04-08 2013-08-29 Boehringer Ingelheim International Gmbh Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists
ES2639617T3 (es) * 2010-10-12 2017-10-27 Merz Pharma Gmbh & Co. Kgaa Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos
MX2013010306A (es) * 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
CN103702995B (zh) 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN107496421A (zh) 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
PT3113773T (pt) 2014-03-06 2019-11-12 Aratana Therapeutics Inc Formas cristalinas do grapiprant

Also Published As

Publication number Publication date
US20160317559A1 (en) 2016-11-03
PT3113774T (pt) 2022-02-28
ES2907285T3 (es) 2022-04-22
NZ761827A (en) 2021-03-26
EP3113774A1 (en) 2017-01-11
AU2015227059B2 (en) 2018-11-15
RU2016137926A (ru) 2018-04-09
WO2015134792A1 (en) 2015-09-11
RU2019102384A (ru) 2019-03-04
CN112370450A (zh) 2021-02-19
KR102270323B1 (ko) 2021-06-29
CA2941008A1 (en) 2015-09-11
PL3113774T3 (pl) 2022-06-13
MX2016011025A (es) 2016-11-29
NZ724007A (en) 2021-02-26
JP2017507190A (ja) 2017-03-16
TW201603812A (zh) 2016-02-01
KR20160129887A (ko) 2016-11-09
TW201815393A (zh) 2018-05-01
RU2679631C2 (ru) 2019-02-12
RU2019102384A3 (es) 2022-03-31
JP6419857B2 (ja) 2018-11-07
EP3113774A4 (en) 2017-10-25
US11369621B2 (en) 2022-06-28
TWI664969B (zh) 2019-07-11
CA2941008C (en) 2022-07-26
EP3113774B1 (en) 2022-01-26
CN105939713A (zh) 2016-09-14
DK3113774T3 (da) 2022-03-07
AU2015227059A1 (en) 2016-09-22
US20150250773A1 (en) 2015-09-10
MX2022014763A (es) 2023-01-11
TWI708606B (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016500910A1 (en) Long-acting ketoprofen compositions
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
IN2013MU03428A (es)
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
IN2013MU03429A (es)
IN2014DE00822A (es)